Item 7.01 Regulation FD Disclosure.

Pieris Pharmaceuticals, Inc. ("Pieris") and Genentech, Inc. previously entered into a Research Collaboration and License Agreement to discover, develop and commercialize locally delivered respiratory therapies that leverage Pieris' proprietary Anticalin® technology. In May 2023, the respiratory program was jointly discontinued for scientific reasons. Furnished hereto as Exhibit 99.1 is the June 2023 Investor Presentation of Pieris.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.


--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Investor Presentation, dated June 2023.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses